Kaitlin A Greene1, Carlyn P Gentile2, Christina L Szperka2, Marcy Yonker3, Amy A Gelfand4, Barbara Grimes5, Samantha L Irwin6. 1. Division of Pediatric Neurology, Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon. 2. Pediatric Headache Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Pediatric Headache Program, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado. 4. Child and Adolescent Headache Program, University of California, San Francisco, California. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco, California. 6. Child and Adolescent Headache Program, University of California, San Francisco, California. Electronic address: Samantha.irwin@ucsf.edu.
Abstract
BACKGROUND: Monoclonal antibodies to calcitonin gene-related peptide or its receptor have clinical trial evidence in adults with headache, but data are lacking in adolescents. The objective of this study was to describe the safety and efficacy of calcitonin gene-related peptide monoclonal antibody treatment in adolescents with chronic headache disorders. METHODS: We performed a retrospective multisite cohort study of patients less than 18 years of age who received a calcitonin gene-related peptide monoclonal antibody for headache prevention. Demographics, baseline headache characteristics, efficacy, and side effect data were collected. RESULTS: The study population comprised 112 adolescents who received at least one dose of a calcitonin gene-related peptide monoclonal antibody. Mean (S.D.; range) age at first dose was 15.9 years (1.4; 10.3 to 17.8). Ninety-four patients (83.9%) had chronic migraine, 12 (10.7%) had new daily persistent headache, and six (5.4%) had persistent post-traumatic headache. At baseline, the mean (S.D.) number of headache days per month was 26.9 (6.1) (n = 109) and headache was continuous in 75 of 111 (67.6%). At first follow-up visit there was a significant reduction in headache frequency compared with baseline (-2.0 days; 95% confidence interval, -0.8 to -3.2). Significant benefit was perceived by 29.5% of patients at first follow-up visit (n = 33/112) and 30.1% (n = 22/73) at second follow-up visit. A significant functional improvement was perceived by 31% of patients (n = 31/94) at the first follow-up visit and 22.4% (n = 15/67) at the second follow-up visit. The most common side effects were injection site reactions in 17.0% (n = 19) and constipation in 8.0% (n = 9). Five patients (4.5%) discontinued because of side effects. CONCLUSIONS: Side effects with calcitonin gene-related peptide monoclonal antibody treatment in adolescents were similar to those reported in adult trials. Calcitonin gene-related peptide monoclonal antibody treatment appears to benefit a proportion of adolescents with chronic refractory headache disorders.
BACKGROUND: Monoclonal antibodies to calcitonin gene-related peptide or its receptor have clinical trial evidence in adults with headache, but data are lacking in adolescents. The objective of this study was to describe the safety and efficacy of calcitonin gene-related peptide monoclonal antibody treatment in adolescents with chronic headache disorders. METHODS: We performed a retrospective multisite cohort study of patients less than 18 years of age who received a calcitonin gene-related peptide monoclonal antibody for headache prevention. Demographics, baseline headache characteristics, efficacy, and side effect data were collected. RESULTS: The study population comprised 112 adolescents who received at least one dose of a calcitonin gene-related peptide monoclonal antibody. Mean (S.D.; range) age at first dose was 15.9 years (1.4; 10.3 to 17.8). Ninety-four patients (83.9%) had chronic migraine, 12 (10.7%) had new daily persistent headache, and six (5.4%) had persistent post-traumatic headache. At baseline, the mean (S.D.) number of headache days per month was 26.9 (6.1) (n = 109) and headache was continuous in 75 of 111 (67.6%). At first follow-up visit there was a significant reduction in headache frequency compared with baseline (-2.0 days; 95% confidence interval, -0.8 to -3.2). Significant benefit was perceived by 29.5% of patients at first follow-up visit (n = 33/112) and 30.1% (n = 22/73) at second follow-up visit. A significant functional improvement was perceived by 31% of patients (n = 31/94) at the first follow-up visit and 22.4% (n = 15/67) at the second follow-up visit. The most common side effects were injection site reactions in 17.0% (n = 19) and constipation in 8.0% (n = 9). Five patients (4.5%) discontinued because of side effects. CONCLUSIONS: Side effects with calcitonin gene-related peptide monoclonal antibody treatment in adolescents were similar to those reported in adult trials. Calcitonin gene-related peptide monoclonal antibody treatment appears to benefit a proportion of adolescents with chronic refractory headache disorders.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Peter J Goadsby; Uwe Reuter; Yngve Hallström; Gregor Broessner; Jo H Bonner; Feng Zhang; Sandhya Sapra; Hernan Picard; Daniel D Mikol; Robert A Lenz Journal: N Engl J Med Date: 2017-11-30 Impact factor: 91.245
Authors: Virginia L Stauffer; David W Dodick; Qi Zhang; Jeffrey N Carter; Jessica Ailani; Robert R Conley Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Natalie J Wiendels; Martine C M van der Geest; Arie Knuistingh Neven; Michel D Ferrari; Laura A E M Laan Journal: Headache Date: 2005-06 Impact factor: 5.887
Authors: Stewart Tepper; Messoud Ashina; Uwe Reuter; Jan L Brandes; David Doležil; Stephen Silberstein; Paul Winner; Dean Leonardi; Daniel Mikol; Robert Lenz Journal: Lancet Neurol Date: 2017-04-28 Impact factor: 44.182
Authors: Richard B Lipton; Aubrey Manack; Judith A Ricci; Elsbeth Chee; Catherine C Turkel; Paul Winner Journal: Headache Date: 2011-05 Impact factor: 5.887
Authors: Andrew D Hershey; Scott W Powers; Christopher S Coffey; Dixie D Eklund; Leigh Ann Chamberlin; Leslie L Korbee Journal: Headache Date: 2013-04-17 Impact factor: 5.887
Authors: Donald Lewis; Paul Winner; Joel Saper; Seth Ness; Elena Polverejan; Steven Wang; Caryn L Kurland; Jeff Nye; Eric Yuen; Marielle Eerdekens; Lisa Ford Journal: Pediatrics Date: 2009-03 Impact factor: 7.124
Authors: Maryam Oskoui; Tamara Pringsheim; Lori Billinghurst; Sonja Potrebic; Elaine M Gersz; David Gloss; Yolanda Holler-Managan; Emily Leininger; Nicole Licking; Kenneth Mack; Scott W Powers; Michael Sowell; M Cristina Victorio; Marcy Yonker; Heather Zanitsch; Andrew D Hershey Journal: Headache Date: 2019-09 Impact factor: 5.887
Authors: Maximilian David Mauritz; Carola Hasan; Lutz Schreiber; Andreas Wegener-Panzer; Sylvia Barth; Boris Zernikow Journal: Children (Basel) Date: 2022-03-18